Rapidly advancing pipeline of investigational precision therapies

DRUG CANDIDATE (TARGET)	Discovery	Early stage clinical development	Late stage clinical development	Regulatory submission	Approved	Commercial rights
Avapritinib (KIT & PDGFRA)	PDGFRA Exon 18 mutant GIST[1]			NDA planned Q2 2019		*
	4L GIST[1]			NDA planned Q2 2019		
	3L GIST[1]			NDA planned 2020		
	2L GIST[1]		Trial planned 2H 2019			
	Advanced SM			NDA planned Q1 2020		
	Indolent and smoldering SM					
BLU-667 (RET)	2L RET-fusion NSCLC[1]			NDA planned Q1 2020		**
	1L RET-fusion NSCLC[1] – Trial planned 2H 2019					
	EGFR-m NSCLC (+osimertinib)[1] – Trial planned 2H 2019					
	2L RET-mutant MTC[1]			NDA planned 1H 2020		
	Other RET-altered solid tumors[1]					
BLU-554 (FGFR4)	Advanced HCC					
	Advanced HCC (+CS-1001) – Trial planned 2H 2019					
BLU-782 (ALK2)	FOP[2]					*
4 wholly owned programs	Undisclosed targets					
Cancer immunotherapy	Up to 5 cancer immunotherapy programs; development stage undisclosed					* Roche **

EGFR-m, EGFR mutant; FOP, fibrodysplasia ossificans progressiva; HCC, hepatocellular carcinoma. [1]Unresectable or metastatic disease. [2]Phase 1 trial in healthy volunteers ongoing; phase 2 trial in patients with FOP planned Q4 2019.

*CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains all rights in the rest of the world.

**Blueprint Medicines has U.S. commercial rights for up to two programs. Roche has worldwide commercialization rights for up to three programs and ex-U.S. commercialization rights for up to two programs.